NCT05154383 - Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

July 21, 2022

Study Completion Date

July 21, 2022

Conditions

Vaccine Reaction

Interventions

BIOLOGICAL

Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)

Patient will received one dose of High Dose Quadrivalent Influenza Vaccine according to marketing authorization.

BIOLOGICAL

Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine

Patient will received one dose of Standard Dose Quadrivalent Influenza Vaccine according to marketing authorization.

Trial Locations (2)

Centre Hospitalier Annecy Genevois, Annecy

Centre Hospitalier Métropole Savoie, Chambéry